The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein]
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]]
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein]
cangrelor results in decreased expression of and results in decreased activity of F3 protein; Indomethacin promotes the reaction [cangrelor results in decreased expression of and results in decreased activity of F3 protein]
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased abundance of phosphatidylinositol 3,4,5-triphosphate; [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein P2RY12 gene polymorphism affects the susceptibility to cangrelor cangrelor results in decreased activity of P2RY12 protein
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]
ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel] [Aspirin results in increased expression of ABCB1 protein] which results in decreased uptake of clopidogrel ABCB1 protein results in decreased uptake of clopidogrel clopidogrel results in decreased expression of ABCB1 mRNA; clopidogrel results in decreased expression of ABCB1 protein ABCB1 protein results in increased secretion of clopidogrel clopidogrel results in decreased activity of ABCB1 protein ABCB1 gene affects the susceptibility to clopidogrel; ABCB1 gene polymorphism affects the susceptibility to clopidogrel; ABCB1 gene SNP affects the susceptibility to clopidogrel
clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein] clopidogrel results in decreased expression of CD40LG protein Clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CD40LG protein]
CYP1A2 protein results in increased oxidation of and results in increased cleavage of Clopidogrel metabolite; furafylline inhibits the reaction [CYP1A2 protein results in increased oxidation of Clopidogrel] CYP1A2 protein results in increased oxidation of clopidogrel
CYP2B6 protein results in increased oxidation of clopidogrel Clopidogrel results in increased expression of CYP2B6 mRNA [Clopidogrel co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA
ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; CYP2C19 gene affects the reaction [clopidogrel affects the phosphorylation of VASP protein]; CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene polymorphism results in decreased metabolism of and results in decreased activity of clopidogrel; CYP2C19 gene SNP promotes the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel]; CYP2C19 protein results in increased metabolism of and results in increased activity of clopidogrel; CYP2C19 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite; CYP2C9 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; N-3-benzylnirvanol inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel]; P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel] CYP2C19 protein results in increased metabolism of clopidogrel CYP2C19 gene polymorphism results in decreased susceptibility to clopidogrel; CYP2C19 gene SNP results in decreased susceptibility to clopidogrel CYP2C19 gene polymorphism results in increased susceptibility to clopidogrel; CYP2C19 gene SNP results in increased susceptibility to clopidogrel CYP2C19 gene polymorphism results in decreased metabolism of clopidogrel; CYP2C19 gene SNP results in decreased metabolism of clopidogrel CYP2C19 gene polymorphism affects the abundance of clopidogrel metabolite CYP2C19 gene affects the susceptibility to clopidogrel; CYP2C19 gene polymorphism affects the susceptibility to clopidogrel; CYP2C19 gene SNP affects the susceptibility to clopidogrel
CYP3A5 gene polymorphism affects the susceptibility to clopidogrel CYP3A5 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite
clopidogrel promotes the reaction [Silicon Dioxide analog results in increased expression of IL6 protein] clopidogrel results in decreased expression of IL6 mRNA IL6 protein results in increased susceptibility to clopidogrel clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate]; ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Epinephrine]; ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel]
Clopidogrel inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of MPO protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein]
Clopidogrel affects the localization of NR1I3 protein mutant form [Clopidogrel co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA; Clopidogrel binds to and results in increased activity of NR1I3 protein alternative form; Clopidogrel inhibits the reaction [ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate results in decreased activity of NR1I3 protein]; Clopidogrel promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]
clopidogrel results in decreased expression of OCLN protein SB 203580 inhibits the reaction [clopidogrel results in decreased expression of OCLN protein]
clopidogrel binds to and results in decreased activity of P2RY12 protein; P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel] P2RY12 protein results in increased susceptibility to clopidogrel P2RY12 gene affects the susceptibility to clopidogrel; P2RY12 gene SNP affects the susceptibility to clopidogrel; P2RY12 protein affects the susceptibility to clopidogrel
PON1 gene polymorphism affects the susceptibility to clopidogrel PON1 protein results in increased metabolism of and results in increased activity of clopidogrel
Clopidogrel inhibits the reaction [F2 protein results in increased expression of SELP protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of SELP protein] clopidogrel results in decreased expression of SELP mRNA; clopidogrel results in decreased expression of SELP protein
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TGFB1 mRNA] clopidogrel results in increased expression of TGFB1 mRNA
clopidogrel results in increased expression of THBS1; clopidogrel results in increased expression of THBS1 mRNA; clopidogrel results in increased expression of THBS1 protein
clopidogrel results in decreased expression of TJP1 protein SB 203580 inhibits the reaction [clopidogrel results in decreased expression of TJP1 protein]
clopidogrel results in increased expression of TNF mRNA Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3]; Suramin inhibits the reaction [Clodronic Acid results in increased expression of CASP3]
Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of IL10 protein] Suramin results in decreased activity of IL10 protein
Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Silicon Dioxide analog results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] Suramin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK1 protein] Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein] Suramin inhibits the reaction [2,6-di-tert-butyl-4-hydroperoxy-4-methyl-2,5-cyclohexadienone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein]
Suramin inhibits the reaction [arsenic acid results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [arsenite results in increased activity of MAPK3 protein]; Suramin inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased phosphorylation of MAPK3 protein] Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein] Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]
JTE 013 promotes the reaction [Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Suramin inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin promotes the reaction [JTE 013 inhibits the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]
Suramin inhibits the reaction [sodium arsenite results in increased phosphorylation of SHC1 protein] Suramin results in increased expression of SHC1 mRNA; Suramin results in increased expression of SHC1 protein
Suramin inhibits the reaction [LMNA protein binds to and results in increased activity of SIRT1 protein]; Suramin results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein] [Suramin results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol
Ticagrelor inhibits the reaction [4-nitrobenzylthioinosine binds to SLC29A1 protein]; Ticagrelor inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]
Ticlopidine results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Ticlopidine results in increased activity of CASP3 protein]
Ticlopidine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Ticlopidine results in increased activity of CASP7 protein]
CYP1A2 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ticlopidine inhibits the reaction [CYP1A2 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] Ticlopidine results in decreased activity of CYP1A2 protein
Ticlopidine binds to and results in decreased activity of CYP2B6 protein; Ticlopidine inhibits the reaction [CYP2B6 protein affects the metabolism of Endosulfan]; Ticlopidine inhibits the reaction [CYP2B6 protein results in increased metabolism of Bupropion] Ticlopidine results in decreased activity of CYP2B6 protein
CYP2C19 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Ticlopidine inhibits the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] Ticlopidine results in decreased activity of CYP2C19 protein
CYP2D6 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite Ticlopidine results in decreased activity of CYP2D6 protein
1-aminobenzotriazole inhibits the reaction [[Ticlopidine co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Ticlopidine results in increased expression of HMOX1 mRNA]
browse the term
